- Report
- October 2021
- 897 Pages
France
From €3405EUR$3,500USD£2,917GBP
- Report
- October 2021
- 997 Pages
United States
From €4378EUR$4,500USD£3,751GBP
- Report
- October 2021
- 886 Pages
United Kingdom
From €3405EUR$3,500USD£2,917GBP
- Report
- April 2022
- 210 Pages
Global
From €5613EUR$5,769USD£4,809GBP
From €6001EUR$6,168USD£5,141GBP
The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics.
The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection.
Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more